EQS — News: SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug — Coated Balloons in Complex Coronary Disease

EQS-News: Translumina / Key word(s): Miscellaneous SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease 12.10.2026 / 20:05 CET/CEST The issuer is solely responsible for the content of this announcement. ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════ LUCERNE, Switzerland and NEW DELHI, Oct. 12, 2026 // — The SPARX Global Randomized Controlled Trial (RCT) has been officially initiated, marking the launch of the multinational randomized trial evaluating a drug-coated balloon (DCB)-first strategy against contemporary drug-eluting stents (DES) in patients with complex coronary artery disease.Designed to generate comparative evidence, SPARX aims to address key unanswered clinical questions regarding the safety, efficacy, and long-term outcomes of a "leave nothing behind" treatment strategy, with the potential to shape future clinical practice and international guideline recommendations. 1 Translumina Logo As one of the contemporary multinati